Nathan Seppa has been the biomedical writer at Science News since 1997. Previously, he worked at the Wisconsin State Journal, a daily newspaper in Madison, where he inaugurated the science beat. In the 1980s, he covered energy and economics for the Dow Jones News Service in the Wall Street Journal's Washington Bureau. In the 1970s, Seppa served as a public health volunteer in the Peace Corps in Zaire, now Congo. He hails from the Upper Peninsula of Michigan, where he worked as a miner and gravedigger to pay his way through college. He has a B.S. in Sociology and a M.A. in Journalism. Nathan speaks French and knows enough Swahili to get out of a tight spot.
Nathan Seppa's Articles
- NewsTwo new tests, on blood and urine, detect the presence of synthetic erythropoietin, a drug that boosts red blood cell counts and enhances stamina.
- NewsA comparison of strains of Helicobacter pylori, the bacterium that causes ulcers, suggests that colonists brought it to the New World.
- NewsIn its first large-scale test on newly diagnosed leukemia patients, the drug imatinib—also called Gleevec and STI-571—stopped or reversed the disease in nearly all patients receiving it.
- NewsA tiny disposable flash camera that a person swallows can detect problems in the small intestine.
- NewsUsing a scanning technology called microcomputerized tomography, scientists have a new way to look at the difference between bone exposed to estrogen and bone deprived of it.
- NewsTests in cows suggest that tetracycline might kill the tiny worm that spreads river blindness, a disease that infects about 18 million people.
- NewsA new brain-imaging technique can supply proof of Parkinson's disease in people whose symptoms fall short of the standard definition of the disease.
- NewsBy unleashing radio waves inside bone, researchers have stopped intractable pain in people with cancer that has spread to their skeletons.
- NewsWhile levodopa is the treatment of choice for Parkinson's disease, drugs called dopamine agonists, which mimic the neurotransmitter dopamine, may work as well early in the disease, cause fewer side effects, and preserve levodopa's effectiveness.
- NewsCoronary bypass surgery works as well in people over age 75 as it does in people 15 years younger.